Octreotide Depot

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, Novartis Pharmaceuticals

Conditions

Islet Cell CarcinomaNeuroendocrine CarcinomaNeuroendocrine TumorPancreatic Neoplasms

Phase 2

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

CompletedNCT00113360

M.D. Anderson Cancer CenterIslet Cell Carcinoma, Neuroendocrine Carcinoma

Start: 2005-01-31End: 2009-07-31Updated: 2025-05-01

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

CompletedNCT00363051

Novartis PharmaceuticalsIslet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor +1

Start: 2006-06-30End: 2012-04-30Updated: 2013-05-10